Roche $ 5.3 billion contract for Zealand Pharma Strike obesity

Swiss drug giant Roche On Wednesday that the Danish biotech has hit up to 5.3 billion dollars to develop biotech development Zealand PharmaObesity candidate candidate, the two companies wanted to compete as a result of a loss of weight loss.

The deal will see the joint development and combination of the two companies Petrelintide, Zealand Pharra amillin analogue Like a connected therapy, as well as the Roche’s lead innest innest connection with a fixed dose with CT-388.

According to the agreement, Zealand Pharma, $ 1.65 billion, $ 1.65 billion, the potential of the potential capacity of the potential capacity of the potential capacity of the potential of the potential of the potential of the potential, Faz-3 tests and sales, Roche said.

Zealand added Pharma shares by 33.5%, while Roche added 5.3%.

Stockings of obesity medicinal giant Novo NordiskMeanwhile, 3.9% slipped at a meeting on Wednesday Eli lilli 1.5% decreased in trade before the market.

Zealand Pharma CEO and President Adam Steensberg told CNBC that the contract showed a strong commitment to the future of two companies in the future. “

“Roche convinced us that they were deprived of leadership in this therapeutic space,” Steensberg told CNBC via CNBC via video call on Wednesday.

The global therapy area in Roche is heading and cardiovascular, kidney and metabolic (CVRM) product development, both independent treatment, but also will be added to the Petrelintide “Complementary” portfolio.

Steensberg Sain Zealand has received a “high interest rate” since its partnership discussions last year. However, Roche noted that he was “most desirable” with reference to the Swiss company Previous developments Getting the GLP-1 manufacturer in the drug market, including the manufacturer of carmot therapeutics.

He added that the partnership with Sunday leaders with Novo or Lilly was “not possible”, accordingly, the existing GLP-1 obesity drug franchise.

Bank of America Securities Celebrated the Roche Partnership on Wednesday, GLP-1S and a “best job scenario”, taking into account the work between the mechanisms.

The expected bargaining, Roche and Zelandan in the United States and Europe in the second quarter traded with two shareholders and losses based on 50/50 in the US and Europe. Roche will acquire exclusive trade rights in the rest of the world.

Zealand Pharma has long pointed to amillin analogues “The next generation” weight loss treatment. They are working by imitating a hormone that combines with insulin in the pancreas to increase grumpy. It differs from GLP-1 agonists that imitate the hormones that imitate the hormones produced in the gut to suppress the appetite and adjust blood sugar.

“Unlike GLP-1S, which makes people without appetite, Petrelintide can help people feel faster than himself,” Steensberg said.

With the new treatment, the two companies hope to better respond to the heterogeneous requirements of obesity treatment and heterogeneous requirements of the comorboards related to the heterogeneous.

“It’s not just about weight. You need it to some extent, but the quality of weight loss, the sustainability of the response, through the ability to switch between mechanisms, video calls,” he said.

Petrelintide, currently passes through two testing stages with Phase 4. Steensberg said that companies hope to bring the product to the market until 2030.

BOFA analysts were a separate note on Wednesday that Zealand PharreRelintide was “potentially the best in the factor”, about 20% Phase three weight losses as monotherapy.

Novo Nordiskin Novo Nordisk’s next generation of obesity Drugs Cagrisema is coming after a second late-stage test Disappointing investors The expected weight loss loss on Monday noted lower than the results.

After the latest readings, the shares fell more than 6%, the obese or overweight adult patients with type 2 diabetes were lower than in 68%, 15.7% of their weight decreased after 25% Previously forecasting.